Travere Therapeutics (NASDAQ:TVTX) Insider Jula Inrig Sells 1,018 Shares

Travere Therapeutics, Inc. (NASDAQ:TVTX) insider Jula Inrig sold 1,018 shares of the business’s stock in a transaction that occurred on Wednesday, April 15th. The stock was sold at an average price of $42.61, for a total transaction of $43,376.98. Following the transaction, the insider owned 111,473 shares of the company’s stock, valued at approximately $4,749,864.53. This trade represents a 0.90% decrease in their position. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is available through this hyperlink. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. The sale was made to cover tax withholding obligations related to the vesting of equity awards.

Jula Inrig also recently made the following trade(s):

• On Tuesday, April 14th, Jula Inrig sold 7,215 shares of Travere Therapeutics stock. The stock was sold at an average price of $41.93, for a total transaction of $302,524.95.
• On Wednesday, February 4th, Jula Inrig sold 1,779 shares of Travere Therapeutics stock. The stock was sold at an average price of $32.21, for a total transaction of $57,301.59.
• On Tuesday, February 3rd, Jula Inrig sold 6,956 shares of Travere Therapeutics stock. The stock was sold at an average price of $32.12, for a total transaction of $223,426.72.

Travere Therapeutics Trading Down 2.8%

NASDAQ TVTX opened at $40.95 on Thursday. The company has a quick ratio of 2.70, a current ratio of 2.74 and a debt-to-equity ratio of 2.71. The firm has a market cap of $3.78 billion, a PE ratio of -136.50 and a beta of 0.86. The company has a 50 day moving average price of $29.57 and a 200 day moving average price of $31.37. Travere Therapeutics, Inc. has a 52 week low of $13.88 and a 52 week high of $43.31.

Wall Street Analyst Weigh In

TVTX has been the topic of a number of recent analyst reports. Guggenheim upped their price target on shares of Travere Therapeutics from $49.00 to $54.00 and gave the company a “buy” rating in a research note on Tuesday. Citigroup upped their price target on shares of Travere Therapeutics from $48.00 to $53.00 and gave the company a “buy” rating in a research note on Tuesday. HC Wainwright restated a “buy” rating and set a $47.00 price target on shares of Travere Therapeutics in a research note on Tuesday. Wall Street Zen lowered shares of Travere Therapeutics from a “strong-buy” rating to a “buy” rating in a research note on Saturday, February 21st. Finally, Wedbush upped their price target on shares of Travere Therapeutics from $39.00 to $44.00 and gave the company an “outperform” rating in a research note on Tuesday. Eleven research analysts have rated the stock with a Buy rating, two have assigned a Hold rating and one has given a Sell rating to the company’s stock. According to data from MarketBeat, Travere Therapeutics has an average rating of “Moderate Buy” and a consensus price target of $42.50.

More Travere Therapeutics News

Here are the key news stories impacting Travere Therapeutics this week:

• Positive Sentiment: FDA grants full approval for Filspari in focal segmental glomerulosclerosis (FSGS), expanding Travere’s rare kidney-disease franchise, adding an estimated ~30,000 patients to the U.S. addressable market and supporting multi-year revenue/earnings upside. Article Title
• Positive Sentiment: Market reacted strongly to the approval — shares jumped about ~37% on the news as investors priced in first-mover status, premium pricing potential and material volume-driven revenue growth for Filspari. Article Title
• Positive Sentiment: Multiple brokerages raised ratings/price targets following the approval (examples: Canaccord to $56, Guggenheim to $54, Piper Sandler to $49 overweight, Wedbush to $44, HC Wainwright reaffirmed buy). These upgrades signal increased analyst confidence in TAM expansion and revenue trajectory. Article Title
• Neutral Sentiment: Guggenheim issued a positive forecast note on TVTX that accompanies their price-target lift; this is incremental institutional support but not a guarantee of sustained momentum. Article Title
• Neutral Sentiment: Unusually high options activity and elevated trading volume were reported around the approval-related move, indicating heightened short-term speculation and positioning that can amplify volatility. Article Title
• Neutral Sentiment: Company-hosted commentary/transcripts and mainstream coverage (Seeking Alpha slides/transcript, MSN health reports) are providing more detail on label scope and commercial plans; useful for modeling uptake but not yet concrete sales figures. Article Title
• Negative Sentiment: Some analysts caution that recent earnings-estimate revision trends may limit further near-term upside despite the approval; elevated expectations and heavy short-term speculative flows raise the risk of a pullback or consolidation. Article Title

Institutional Trading of Travere Therapeutics

Large investors have recently made changes to their positions in the business. State of Wyoming purchased a new stake in shares of Travere Therapeutics in the 4th quarter valued at $37,000. Torren Management LLC purchased a new stake in shares of Travere Therapeutics in the 4th quarter valued at $38,000. Comerica Bank boosted its holdings in shares of Travere Therapeutics by 77.5% in the 4th quarter. Comerica Bank now owns 1,127 shares of the company’s stock valued at $43,000 after acquiring an additional 492 shares during the last quarter. Smartleaf Asset Management LLC boosted its holdings in shares of Travere Therapeutics by 69.0% in the 4th quarter. Smartleaf Asset Management LLC now owns 1,193 shares of the company’s stock valued at $45,000 after acquiring an additional 487 shares during the last quarter. Finally, First Horizon Corp purchased a new stake in shares of Travere Therapeutics in the 3rd quarter valued at $36,000.

Travere Therapeutics Company Profile

Travere Therapeutics, Inc (NASDAQ: TVTX) is a biopharmaceutical company headquartered in San Diego, California, dedicated to the development and commercialization of therapies for rare kidney and genetic disorders. The company’s mission is to address unmet needs in conditions with limited treatment options by focusing on diseases that affect small patient populations. Travere combines research, development and commercial capabilities to bring innovative medicines to market.

The company’s lead product is sparsentan, a dual endothelin angiotensin receptor antagonist that has received accelerated approval from the U.S.